These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22932002)

  • 21. Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP.
    Mester A; Lucaciu O; Ciobanu L; Apostu D; Ilea A; Campian RS
    Bosn J Basic Med Sci; 2018 Aug; 18(3):217-223. PubMed ID: 29984679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.
    Innes H; Barclay ST; Hayes PC; Fraser A; Dillon JF; Stanley A; Bathgate A; McDonald SA; Goldberg D; Valerio H; Fox R; Kennedy N; Bramley P; Hutchinson SJ
    J Hepatol; 2018 Apr; 68(4):646-654. PubMed ID: 29155019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma.
    Nagao Y; Nakasone K; Maeshiro T; Nishida N; Kimura K; Kawahigashi Y; Tanaka Y; Sata M
    Case Rep Gastroenterol; 2017; 11(3):701-710. PubMed ID: 29430221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection.
    Hayashi T; Tamori A; Nishikawa M; Morikawa H; Enomoto M; Sakaguchi H; Habu D; Kawada N; Kubo S; Nishiguchi S; Shiomi S
    Liver Int; 2009 Jan; 29(1):126-32. PubMed ID: 18492017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
    Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
    Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of cellular proliferative activity in patients with oral lichen planus and hepatitis C through AgNOR method.
    Carli JP; Silva SO; Linden MS; Busin CS; Paranhos LR; Souza PH
    Braz Dent J; 2014; 25(6):461-5. PubMed ID: 25590189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.
    Velosa J; Serejo F; Marinho R; Nunes J; Glória H
    Dig Dis Sci; 2011 Jun; 56(6):1853-61. PubMed ID: 21374066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C and Oral Lichen Planus: Evaluation of their Correlation and Risk Factors in a Longitudinal Clinical Study.
    De Carli JP; Linden MS; da Silva SO; Trentin MS; Matos Fde S; Paranhos LR
    J Contemp Dent Pract; 2016 Jan; 17(1):27-31. PubMed ID: 27084859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
    Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N
    PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
    Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
    Fujiyama S; Tanaka M
    Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma.
    Tomimaru Y; Nagano H; Eguchi H; Kobayashi S; Marubashi S; Wada H; Tanemura M; Umeshita K; Hiramatsu N; Takehara T; Doki Y; Mori M
    J Surg Oncol; 2010 Sep; 102(4):308-14. PubMed ID: 20589711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidepressant use and hepatocellular carcinoma in patients with hepatitis C who had received interferon therapy: A population-based cohort study.
    Chen VC; Lu ML; Yang YH; Weng JC; Chang CC
    J Affect Disord; 2019 Jun; 253():147-153. PubMed ID: 31035215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.